ClinicalTrials.gg
CompletedNCT04092075Updated Jul 29, 2020

Safety and Efficacy of the ToothWave -12 Weeks Calculus Study

An interventional study of RF-utilizing powered toothbrush and Control placebo with no RF in Gingivitis, Plaque and Calculus, Dental, sponsored by Home Skinovations Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-29.

Sponsored by Home Skinovations Ltd. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2020, 6 years 6 months ago, and no results have been posted to the registry.
Phase
Not applicable
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The objective of the study is to evaluate the safety and efficacy of the home-use device Silk'n toothbrush (ToothWave) for the improvement in dental health through the reduction of plaque, gingivitis, and calculus.

Read the detailed description

This is a single blind, prospective study aimed to evaluate the safety and efficacy of the Silk'n toothbrush in reduction of gingivitis, dental plaque and calculus.

The study includes a total of 168 treatment sessions, twice a day, and 5 clinic visits over a period of 12 weeks.

One treatment group (Silk'n toothbrush - ToothWave) and 1 control group (an ADA approved power toothbrush (PTB)) will participate in the study.

For each patient, assessment data will be collected at baseline, 4 weeks, and at 6 weeks. Calculus condition will be measured after 12 weeks in addition to the other timepoints. The average data sets will be calculated for each group.

Treatment is defined as a timed 2 minutes of teeth brushing in a regular manner, twice a day (morning and evening). Brushing will be undertaken using the Silk'n toothbrush and standard fluoride toothpaste. The control group will use a regular PTB and standard fluoride toothpaste.

02

Conditions studied

  • Gingivitis
  • Plaque
  • Calculus, Dental

Browse trials for

03

In context

Gingivitis

631 studies on the registry are indexed under Gingivitis; 107 are open to participants now.

This study's enrollment of 87 is above the median of 66 across 507 interventional studies indexed under Gingivitis.

Browse Gingivitis studies →

Lead sponsor

Home Skinovations Ltd. is the lead sponsor of 11 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult subjects aged 18-70, that are in good health.
  2. Subject must have:

    2.1. Baseline gingivitis (MGI) score of at least 1.80. 2.2. Baseline gingival bleeding (GBI) of ≥1 on at least 20 sites. 2.3. Dental Plaque mean score greater than 0.6 according to the RMNPI (Rustogi Modified Navy Plaque Index).

    2.4. Total Calculus deposits greater than 9 according to the Volpe-Manhold Index.

  3. Have a minimum of 20 'scorable' teeth (excluding 3rd molars).
  4. The subjects should understand the information provided about the investigative nature of the treatment, possible benefits and side effects. Subjects will sign the Form.
  5. The subjects should be willing to comply with the study procedure and schedule, including the follow up visits.

Exclusion criteria

Exclusion Criteria

  1. Current or history of oral cavity cancer or oropharyngeal cancer.
  2. Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body.
  3. Pregnant or nursing by subject report.
  4. Any active condition in the oral cavity at the discretion of the investigator.
  5. Any surgery in the oral cavity within 3 months prior to treatment, or before complete healing.
  6. Subjects that do not brush regularly.
  7. Any condition that might make it unsafe for the subject to participate in this study, at the discretion of the investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    Treatment group

    The treatment is conducted with the ToothWave toothbrush Intervention: brushing with Radio frequency (RF)-utilizing powered toothbrush

    Device: RF-utilizing powered toothbrush

  • Sham comparator
    Control group

    Regular powered toothbrush Intervention: brushing with a regular powered toothbrush with no RF

    Device: Control placebo with no RF

Interventions

  • DeviceRF-utilizing powered toothbrush

    RF-utilizing Powered toothbrush

    Also known as: RF toothbrush

  • DeviceControl placebo with no RF

    Placebo control, toothbrush with no RF

06

What researchers measure

Primary outcomes

  1. Calculus

    A reduction of calculus deposits as compared to control, as evaluated by Volpe-Manhold Index.

    Time frame: 12 weeks

Secondary outcomes

  1. Dental plaque

    A reduction in the level of dental plaque compared to control, according to Rustogi Modification of the Navy.

    Time frame: 6 weeks

  2. Gingival inflammation

    A reduction in the level of gingival inflammation compared to control, according to the Modified Gingival Index (MGI).

    Time frame: 6 weeks

07

Study locations

1 site
  • University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78229-3900, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04092075
Lead sponsor
Home Skinovations Ltd.
Responsible party
Sponsor
First posted
Sep 17, 2019
Start date
Aug 7, 2019
Primary completion
Apr 30, 2020
Completion
Apr 30, 2020
Last update
Jul 29, 2020

Study contacts

Bennett T Amaechi, BDS, MS, PhD
principal investigator · The University of Texas Health Science Center at San Antonio

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion